title: Noradrenergic inhibition of midbrain dopamine neurons.
abstract: Receptors that couple to phosphoinositide hydrolysis, which include metabotropic glutamate receptors (mGluRs) and muscarinic receptors, are known to either activate or inhibit the activity of dopamine cells depending on the pattern of receptor activation. Transient activation of alpha1 adrenoceptors with norepinephrine (NE) resulted in an outward current in midbrain dopamine neurons recorded in brain slices. The NE-mediated outward current was induced by activation of a potassium conductance through release of calcium from intracellular stores. Unlike the mGluR-mediated outward current, the outward current induced by alpha1 adrenoceptors often consisted of multiple peaks. Activation of alpha1 adrenoceptors also induced a wave of calcium release that spread through the soma and proximal dendrites without a decline in amplitude or rate of propagation and therefore differed qualitatively from that induced by mGluRs. Finally, the alpha1 adrenoceptor-activated outward current was more sensitive to the calcium store-depleting agents ryanodine and caffeine. Thus, although both alpha1 adrenoceptors and mGluRs mobilize calcium from intracellular stores, the mechanisms and pools of calcium differ. The results suggest that noradrenergic innervation of dopamine cells can directly inhibit the activity of dopamine cells. Psychostimulants, such as amphetamine, will therefore have a direct effect on the firing pattern of dopamine neurons through a combination of actions on dopamine and alpha1 adrenoceptor activation.
authors.affiliation: The Vollum Institute for Advanced Biomedical Research, Oregon Health and Science University, Portland, Oregon 97201, USA.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Paladini
authors.forename: John T
authors.initials: JT
authors.lastname: Williams
mesh_terms: D000818:Animals; D001030:Apamin / Q000494:pharmacology; D001224:Aspartic Acid / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D020013:Calcium Signaling / Q000502:physiology; D004298:Dopamine / Q000378:metabolism*; D066298:In Vitro Techniques; D007424:Intracellular Fluid / Q000378:metabolism; D008297:Male; D008636:Mesencephalon / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology / Q000502:physiology*; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000378:metabolism; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000378:metabolism*; D018094:Receptors, Metabotropic Glutamate / Q000378:metabolism; D012433:Ryanodine / Q000494:pharmacology
chemical_list: D015221:Potassium Channels; D018340:Receptors, Adrenergic, alpha-1; D018094:Receptors, Metabotropic Glutamate; D012433:Ryanodine; D001030:Apamin; D001224:Aspartic Acid; D002110:Caffeine; D011188:Potassium; D002118:Calcium; D004298:Dopamine; D009638:Norepinephrine